BusinessAmarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESSBy Nasdaq OMXJan 23, 2018, 2:59 PM UTC
